Portfolio company
NMD Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops small molecule therapies for patients suffering from severe neuromuscular disorders to restore skeletal muscle function.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Augustine Therapeutics
This company develops small molecule inhibitors to treat patients with neuromuscular, neurodegenerative and cardio-metabolic diseases.
Enemsa Pharma
This company develops small-molecule neuroprotective therapies and combination drugs to treat patients with rare neurodegenerative and cardiopulmonary diseases.
Dyne
This company develops therapeutics for patients with genetically driven neuromuscular diseases.
Edgewise
This biopharmaceutical company develops oral small molecule therapies to treat patients with rare skeletal and cardiac muscle diseases.
Myosin Therapeutics
This biopharmaceutical company develops small molecule therapies targeting molecular nanomotors to treat aggressive cancers and neurological disorders for patients with unmet medical needs.
NRG Therapeutics
This neuroscience company develops small molecule medicines targeting mitochondrial dysfunction to treat patients with Parkinson's and amyotrophic lateral sclerosis.
Noema Pharma
This company develops clinical-stage therapeutic products for patients with central nervous system disorders and orphan neurological conditions.
Yumanity Therapeutics
This company develops small molecule drugs to treat neurodegenerative diseases for patients with conditions such as Parkinson's disease and amyotrophic lateral sclerosis.